Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II switch-maintenance pembrolizumab after first-line platinum doublet chemotherapy in non-small cell lung cancer
2016-000857-11Phase 2Completed
- Sponsor
- Bank of Cyprus Oncology Centre
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Bank of Cyprus Oncology Centre. Primary endpoint: Percentage of patients without progression at 1 year. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-000857-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000857-11.